This company listing is no longer active
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Cyclacel Pharmaceuticals 관리
관리 기준 확인 2/4
We currently do not have sufficient information about the CEO.
주요 정보
Spiro Rombotis
최고 경영자
US$661.0k
총 보상
| CEO 급여 비율 | 84.7% |
| CEO 임기 | 26.6yrs |
| CEO 소유권 | 2.2% |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 7.5yrs |
최근 관리 업데이트
Recent updates
CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
보상 대 시장: Spiro's total compensation ($USD661.05K) is above average for companies of similar size in the German market ($USD404.23K).
보상과 수익: Spiro's compensation has been consistent with company performance over the past year.
CEO
Spiro Rombotis (64 yo)
26.6yrs
테뉴어
US$661,049
보상
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 18yrs | US$661.05k | 2.19% $ 64.5k | |
| Executive VP of Finance | 18yrs | US$352.62k | 1.19% $ 35.0k | |
| Chief Medical Officer & Director | 3.3yrs | US$101.00k | 0.096% $ 2.8k | |
| Independent Director | 9.5yrs | US$116.50k | 0.32% $ 9.3k | |
| Independent Chairman | 18yrs | US$155.50k | 0.31% $ 9.1k | |
| Independent Director | 3.3yrs | US$95.49k | 0.32% $ 9.3k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데 이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Vice Chairman | 5.5yrs | US$130.75k | 0.31% $ 9.1k | |
| Independent Director | 1.8yrs | US$85.49k | 0.17% $ 4.9k |
7.5yrs
평균 재임 기간
67yo
평균 연령
경험이 풍부한 이사회: UXI's board of directors are considered experienced (7.5 years average tenure).